New insider Stonepine Capital Management, Llc claimed ownership of 3,271,100 units of Ordinary Shares (SEC Form 3)
$QNRX
Medical/Dental Instruments
Health Care
| FORM 3 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
1. Name and Address of Reporting Person*
(Street)
|
2. Date of Event Requiring Statement
(Month/Day/Year) 01/29/2026 |
3. Issuer Name and Ticker or Trading Symbol
Quoin Pharmaceuticals, Ltd. [ QNRX ] |
|||||||||||||
|
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
5. If Amendment, Date of Original Filed
(Month/Day/Year) |
||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Ordinary Shares | 3,271,100(1) | I | See Note(2) |
|
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Pre-Funded Warrants | (3) | (3) | ADS | 81,212(4) | $0.0001 | I | See Note 2 |
| Series H Warrants | (5) | (5) | ADS | 121,212(4) | $9.075 | I | See Note 2 |
| Series I Warrants | (6) | (6) | ADS | 121,212(4) | $10.3125 | I | See Note 2 |
| Series J Warrants | (7) | (7) | ADS | 121,212(4) | $12.375 | I | See Note 2 |
| Series K Warrants | (8) | (8) | ADS | 121,212(4) | $12.375 | I | See Note 2 |
| Explanation of Responses: |
| 1. These Ordinary Shares are held through 93,460 American Depositary Shares ("ADS") of the Issuer. Each ADS represents 35 Ordinary Shares. |
| 2. The reporting persons are Stonepine Capital Management, LLC ("Stonepine"), Stonepine Capital, L.P. (the "Partnership"), Stonepine GP, LLC ("Stonepine GP") and Jon M. Plexico. Stonepine and Stonepine GP are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and Stonepine GP. The Partnership hold these securities directly for the benefit of its investors. Stonepine and Stonepine GP may be deemed to indirectly beneficially own them as the investment adviser and general partner of the Partnership. Mr. Plexico may be deemed to indirectly beneficially own them as the control person of Stonepine and Stonepine GP. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| 3. The pre-funded warrants are exercisable at any time and have no expiration date. |
| 4. Each ADS represents 35 Ordinary Shares. |
| 5. The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance. |
| 6. The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance. |
| 7. The Series J warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance. |
| 8. The Series K warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the Issuer's sale of a Priority Review Voucher (PRV) and (ii) five years from the date of issuance. |
| Remarks: |
| Stonepine is filing this Form 3 for itself, the Partnership, Stonepine GP and Mr. Plexico. The filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934. |
| /s/ Jon M. Plexico, Managing Mermber of Stonepine Capital Management, LLC | 02/02/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||